董事介绍
注:董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Anthony Andolino | 男 | Director and Treasurer | 57 | 未披露 | 未持股 | 2026-07-01 |
| Jonathan Bendheim | 男 | Director and Senior Vice President, Global Technology and Talent | 50 | 未披露 | 未持股 | 2026-07-01 |
| Alejandro Bernal | 男 | Independent Director | 53 | 5.00万美元 | 未持股 | 2026-07-01 |
| E. Thomas Corcoran | 男 | Independent Director | 79 | 5.00万美元 | 未持股 | 2026-07-01 |
| Joyce J. Lee | 女 | Director | 54 | 2.00万美元 | 未持股 | 2026-07-01 |
| Carol A. Wrenn | 女 | Independent Director | 65 | 6.00万美元 | 未持股 | 2026-07-01 |
| Jack C. Bendheim | 男 | Executive Chairman and Director | 79 | 528.41万美元 | 未持股 | 2026-07-01 |
| Daniel M. Bendheim | 男 | Director,Chief Executive Officer and President | 54 | 111.98万美元 | 未持股 | 2026-07-01 |
| Sam Gejdenson | 男 | Independent Director | 77 | 6.00万美元 | 未持股 | 2026-07-01 |
| Mary Lou Malanoski | 女 | Director | 69 | 4.00万美元 | 未持股 | 2026-07-01 |
高管介绍
注:高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Lisa A. Escudero | 女 | Senior Vice President, Human Resources | 64 | 未披露 | 未持股 | 2026-07-01 |
| Anthony Andolino | 男 | Director and Treasurer | 57 | 未披露 | 未持股 | 2026-07-01 |
| Jonathan Bendheim | 男 | Director and Senior Vice President, Global Technology and Talent | 50 | 未披露 | 未持股 | 2026-07-01 |
| Judith A. Weinstein | 女 | Senior Vice President,General Counsel,Corporate Secretary | 57 | 104.39万美元 | 未持股 | 2026-07-01 |
| Glenn David | 男 | Chief Financial Officer | 55 | 127.39万美元 | 未持股 | 2026-07-01 |
| Jack C. Bendheim | 男 | Executive Chairman and Director | 79 | 528.41万美元 | 未持股 | 2026-07-01 |
| Daniel M. Bendheim | 男 | Director,Chief Executive Officer and President | 54 | 111.98万美元 | 未持股 | 2026-07-01 |
| Larry L. Miller | 男 | Chief Operating Officer | 62 | 242.95万美元 | 未持股 | 2026-07-01 |
董事简历
中英对照 |  中文 |  英文- Anthony Andolino
-
Anthony Andolino,Vice President财务和司库。Andolino先生于2011年10月加入我们,担任公司,乙醇性能集团和Phibrochem部门的财务总监。他于2018年3月晋升为Vice President、财务主管和财务主管。从2009年到2011年,他曾担任Huntington Learning Centers公司(教育服务中心)的总会计师。Andolino从2007年到2008年担任Mezz Cap(一家金融管理服务公司)助理财务总监。任职Mezz Cap公司之前,Andolino曾担任Mercer Human Resources Consulting公司的财务总监兼董事(2004年至2007年)。Andolino从1991年到2004年在JD Edwards World Solution Company,The Mony Group和Deloitte&Touche担任多个财务总监和金融职位。他持有Pace University的公共会计B.B.A.学位。他是新泽西州有执照的注册会计师。
Anthony Andolino joined in October 2011 as Controller, Corporate, Ethanol Performance Group and PhibroChem Divisions. He was promoted to Vice President, Finance and Treasurer in March 2018. From 2009 to 2011 he was Controller at Huntington Learning Centers, an educational service center. From 2007 to 2008, Mr. Andolino was an Assistant Controller at Mezz Cap, a financial management service company. Prior to his role at Mezz Cap, Mr. Andolino was a Controller and Director of Finance for Mercer Human Resces Consulting from 2004 to 2007. From 1991 to 2004, Mr. Andolino held vario controller and finance positions at JD Edwards World Solution Company, The MONY Group and Deloitte & Touche. He holds a B.B.A. degree in Public Accounting from Pace University. He is a licensed Certified Public Accountant in the State of New Jersey. - Anthony Andolino,Vice President财务和司库。Andolino先生于2011年10月加入我们,担任公司,乙醇性能集团和Phibrochem部门的财务总监。他于2018年3月晋升为Vice President、财务主管和财务主管。从2009年到2011年,他曾担任Huntington Learning Centers公司(教育服务中心)的总会计师。Andolino从2007年到2008年担任Mezz Cap(一家金融管理服务公司)助理财务总监。任职Mezz Cap公司之前,Andolino曾担任Mercer Human Resources Consulting公司的财务总监兼董事(2004年至2007年)。Andolino从1991年到2004年在JD Edwards World Solution Company,The Mony Group和Deloitte&Touche担任多个财务总监和金融职位。他持有Pace University的公共会计B.B.A.学位。他是新泽西州有执照的注册会计师。
- Anthony Andolino joined in October 2011 as Controller, Corporate, Ethanol Performance Group and PhibroChem Divisions. He was promoted to Vice President, Finance and Treasurer in March 2018. From 2009 to 2011 he was Controller at Huntington Learning Centers, an educational service center. From 2007 to 2008, Mr. Andolino was an Assistant Controller at Mezz Cap, a financial management service company. Prior to his role at Mezz Cap, Mr. Andolino was a Controller and Director of Finance for Mercer Human Resces Consulting from 2004 to 2007. From 1991 to 2004, Mr. Andolino held vario controller and finance positions at JD Edwards World Solution Company, The MONY Group and Deloitte & Touche. He holds a B.B.A. degree in Public Accounting from Pace University. He is a licensed Certified Public Accountant in the State of New Jersey.
- Jonathan Bendheim
-
Jonathan Bendheim是我们的董事会成员,是我们Macie地区的总裁,Macie地区包括中东、非洲、独立国家联合体、印度和欧洲,他是我们在以色列和爱尔兰运营工厂的总经理,并监管Phibro’;的全球水产养殖业务。Bendheim先生于2001年加入Phibro,担任物流和供应链经理。2005年,本德海姆先生被任命为我们以色列业务的销售和业务发展Vice President。2008年他领导从Teva收购ABIC Biological Laboratories,2009年他被任命为我们在以色列运营的董事总经理。2011年,他的职责扩大到包括监督Macie地区的所有销售活动。本德海姆先生于2014年领导成立了Phibro&8217;s全球水产养殖业务,并于2018年创立了Phibro&8217;s PHI-Tech业务部门。Mr.Bendheim持有Yeshiva University政治学学士学位和Columbia Business School工商管理硕士学位。本德海姆先生是JackC.Bendheim的儿子
Jonathan Bendheim serves as a member of Board of Directors and was appointed to the role of Senior Vice President, Global Technology and Talent in September 2024. Previoly, Mr. Bendheim served as President of MACIE Region (which consists of the Middle East, Africa, the Commonalth of Independent States, India and Europe) and was the general manager of operating plants in Israel and Ireland. Mr. Bendheim will continue to oversee his commercial responsibilities as head of the MACIE region until a successor is appointed. Mr. Bendheim will retain operational responsibility for MACIE manufacturing and R&D operations, and Phibro's global aquaculture biness. Mr. Bendheim joined Phibro in 2001 as a Manager for logistics and supply chain. In 2005, Mr. Bendheim was appointed Vice President of Sales and Biness Development for Israel operations. In 2008, he led the acquisition of Abic Biological Laboratories from Teva, and in 2009, he was appointed the Managing Director of operations in Israel. In 2011, his responsibilities re expanded to include oversight of all sales activities in the MACIE Region. Mr. Bendheim led the establishment of Phibro's global aquaculture biness in 2014. Mr. Bendheim holds a B.A. degree in political science from Yeshiva University and an MBA from Columbia Biness School. - Jonathan Bendheim是我们的董事会成员,是我们Macie地区的总裁,Macie地区包括中东、非洲、独立国家联合体、印度和欧洲,他是我们在以色列和爱尔兰运营工厂的总经理,并监管Phibro’;的全球水产养殖业务。Bendheim先生于2001年加入Phibro,担任物流和供应链经理。2005年,本德海姆先生被任命为我们以色列业务的销售和业务发展Vice President。2008年他领导从Teva收购ABIC Biological Laboratories,2009年他被任命为我们在以色列运营的董事总经理。2011年,他的职责扩大到包括监督Macie地区的所有销售活动。本德海姆先生于2014年领导成立了Phibro&8217;s全球水产养殖业务,并于2018年创立了Phibro&8217;s PHI-Tech业务部门。Mr.Bendheim持有Yeshiva University政治学学士学位和Columbia Business School工商管理硕士学位。本德海姆先生是JackC.Bendheim的儿子
- Jonathan Bendheim serves as a member of Board of Directors and was appointed to the role of Senior Vice President, Global Technology and Talent in September 2024. Previoly, Mr. Bendheim served as President of MACIE Region (which consists of the Middle East, Africa, the Commonalth of Independent States, India and Europe) and was the general manager of operating plants in Israel and Ireland. Mr. Bendheim will continue to oversee his commercial responsibilities as head of the MACIE region until a successor is appointed. Mr. Bendheim will retain operational responsibility for MACIE manufacturing and R&D operations, and Phibro's global aquaculture biness. Mr. Bendheim joined Phibro in 2001 as a Manager for logistics and supply chain. In 2005, Mr. Bendheim was appointed Vice President of Sales and Biness Development for Israel operations. In 2008, he led the acquisition of Abic Biological Laboratories from Teva, and in 2009, he was appointed the Managing Director of operations in Israel. In 2011, his responsibilities re expanded to include oversight of all sales activities in the MACIE Region. Mr. Bendheim led the establishment of Phibro's global aquaculture biness in 2014. Mr. Bendheim holds a B.A. degree in political science from Yeshiva University and an MBA from Columbia Biness School.
- Alejandro Bernal
-
Alejandro Bernal自2023年2月起担任董事。Bernal先生还是薪酬委员会的成员。Bernal先生是PetDx- The Liquid Biopsy Company for Pets的首席执行官,PetDx - The Liquid Biopsy Company for Pets总部位于加利福尼亚州圣地亚哥,专注于利用下一代测序(NGS)技术早期检测宠物癌症。加入PetDx之前,Bernal先生曾担任Mars Veterinary Health International and Global Diagnostics总裁,Mars是宠物食品和兽医健康服务领域的全球领导者,任职时间为2018年3月至2022年12月。在Mars期间,他负责在北美以外建立和运营600多家兽医院网络,并负责Antech,Mars是一家在美国、欧洲和亚洲拥有70多个参考实验室的兽医诊断公司。在加入Mars之前,Bernal先生在Zoetis(前身为Pfizer Animal Health)工作了17年,并担任执行团队成员10年。Bernal先生拥有哥伦比亚的Universidad de Caldas兽医学博士学位,美国Texas A&M大学的生理学硕士学位,以及哥伦比亚的Universidad de los Andes和英国曼彻斯特商学院的工商管理硕士学位。
Alejandro Bernal has been a director since February 2023. Mr. Bernal also serves as a member of the Compensation Committee. Since July 2024, Mr. Bernal has also served as the Chief Executive Officer of dgewood Pharmacy, the largest veterinary compounding pharmacy and provider of online pharmacy services based in Sdesboro, NJ. From January 2023 to April 2024, Mr. Bernal was the Chief Executive Officer of PetDx-The Liquid Biopsy Company for Pets, a company based in San Diego, CA, that foced on early detection of cancer ing Next Generation Sequencing (NGS) technology. Prior to joining PetDx, Mr. Bernal was the President for Mars Veterinary Health International and Global Diagnostics, a global leader in pet food and veterinary health services, from March 2018 to December 2022. While at Mars, he was responsible for establishing and operating a network of over 600 veterinary hospitals outside North America and for Antech, a veterinary diagnostics company with over 70 reference labs in the U.S. Prior to Mars, Mr. Bernal worked 17 years for Zoetis Inc. (formerly Pfizer Animal Health, "Zoetis"). He was a member of the Executive Team for 10 years as Area President for Latin America, and then for Europe, Africa and Middle East, and Corporate Development. Mr. Bernal holds a Doctorate in veterinary medicine from Universidad de Caldas (Colombia), a Master's Degree in Physiology from Texas A&M University (A), and an MBA from Universidad de los Andes (Colombia) and Manchester Biness School (UK). - Alejandro Bernal自2023年2月起担任董事。Bernal先生还是薪酬委员会的成员。Bernal先生是PetDx- The Liquid Biopsy Company for Pets的首席执行官,PetDx - The Liquid Biopsy Company for Pets总部位于加利福尼亚州圣地亚哥,专注于利用下一代测序(NGS)技术早期检测宠物癌症。加入PetDx之前,Bernal先生曾担任Mars Veterinary Health International and Global Diagnostics总裁,Mars是宠物食品和兽医健康服务领域的全球领导者,任职时间为2018年3月至2022年12月。在Mars期间,他负责在北美以外建立和运营600多家兽医院网络,并负责Antech,Mars是一家在美国、欧洲和亚洲拥有70多个参考实验室的兽医诊断公司。在加入Mars之前,Bernal先生在Zoetis(前身为Pfizer Animal Health)工作了17年,并担任执行团队成员10年。Bernal先生拥有哥伦比亚的Universidad de Caldas兽医学博士学位,美国Texas A&M大学的生理学硕士学位,以及哥伦比亚的Universidad de los Andes和英国曼彻斯特商学院的工商管理硕士学位。
- Alejandro Bernal has been a director since February 2023. Mr. Bernal also serves as a member of the Compensation Committee. Since July 2024, Mr. Bernal has also served as the Chief Executive Officer of dgewood Pharmacy, the largest veterinary compounding pharmacy and provider of online pharmacy services based in Sdesboro, NJ. From January 2023 to April 2024, Mr. Bernal was the Chief Executive Officer of PetDx-The Liquid Biopsy Company for Pets, a company based in San Diego, CA, that foced on early detection of cancer ing Next Generation Sequencing (NGS) technology. Prior to joining PetDx, Mr. Bernal was the President for Mars Veterinary Health International and Global Diagnostics, a global leader in pet food and veterinary health services, from March 2018 to December 2022. While at Mars, he was responsible for establishing and operating a network of over 600 veterinary hospitals outside North America and for Antech, a veterinary diagnostics company with over 70 reference labs in the U.S. Prior to Mars, Mr. Bernal worked 17 years for Zoetis Inc. (formerly Pfizer Animal Health, "Zoetis"). He was a member of the Executive Team for 10 years as Area President for Latin America, and then for Europe, Africa and Middle East, and Corporate Development. Mr. Bernal holds a Doctorate in veterinary medicine from Universidad de Caldas (Colombia), a Master's Degree in Physiology from Texas A&M University (A), and an MBA from Universidad de los Andes (Colombia) and Manchester Biness School (UK).
- E. Thomas Corcoran
-
E. Thomas Corcoran 自2008年5月起一直担任董事。Corcoran先生还担任审计委员会主席。Corcoran先生于1985年加入Fort Dodge Animal Health( Wyeth的一个部门)。惠氏公司专注于人类健康和动物健康的业务研究。2008年3月退休之前,Corcoran先生任职于 Wyeth的管理、操作、法律和人力资源和福利委员会。Corcoran先生还担任了动物卫生研究所(一个倡导动物健康问题的行业组织)的主席,包括效率和有效的FDA、USDA和EPA的监管和审批程序。Corcoran先生任职普特尼公司的董事会及南阿拉巴马大学的董事会。Corcoran先生也是动物药业终身成就奖的获得者,班菲尔德行业领袖奖,来自美国兽医经销商协会和堪萨斯市动物卫生走廊的产业领袖奖的终身成就奖。Corcoran先生是 University of South Alabama杰出校友奖的获得者。
E. Thomas Corcoran has been a director since May 2008. Mr. Corcoran also serves as Chair of the Audit Committee. Mr. Corcoran joined Fort Dodge Animal Health, a division of Wyeth, Inc., as its President in 1985. Wyeth was a research based corporation with binesses foced on human health and animal health. Mr. Corcoran served on the Management, the Operations, the Legal, and the Human Resces and Benefits committees of Wyeth until his retirement in March 2008. From 2008 until 2010, Mr. Corcoran was a member of the Board of Directors of AHI, Inc., a veterinary distribution company. From 2010 until 2016, Mr. Corcoran was a director of Putney, Inc., a pet pharmaceutical company. Mr. Corcoran also served as the Chairman of the Animal Health Institute, an indtry organization advocating for animal health issues, including efficient and effective FDA, DA and EPA regulatory and approval processes. Since 2009, Mr. Corcoran has served on the Board of Trtees of the University of South Alabama, where he is Chairman of the Finance and Budget committee. - E. Thomas Corcoran 自2008年5月起一直担任董事。Corcoran先生还担任审计委员会主席。Corcoran先生于1985年加入Fort Dodge Animal Health( Wyeth的一个部门)。惠氏公司专注于人类健康和动物健康的业务研究。2008年3月退休之前,Corcoran先生任职于 Wyeth的管理、操作、法律和人力资源和福利委员会。Corcoran先生还担任了动物卫生研究所(一个倡导动物健康问题的行业组织)的主席,包括效率和有效的FDA、USDA和EPA的监管和审批程序。Corcoran先生任职普特尼公司的董事会及南阿拉巴马大学的董事会。Corcoran先生也是动物药业终身成就奖的获得者,班菲尔德行业领袖奖,来自美国兽医经销商协会和堪萨斯市动物卫生走廊的产业领袖奖的终身成就奖。Corcoran先生是 University of South Alabama杰出校友奖的获得者。
- E. Thomas Corcoran has been a director since May 2008. Mr. Corcoran also serves as Chair of the Audit Committee. Mr. Corcoran joined Fort Dodge Animal Health, a division of Wyeth, Inc., as its President in 1985. Wyeth was a research based corporation with binesses foced on human health and animal health. Mr. Corcoran served on the Management, the Operations, the Legal, and the Human Resces and Benefits committees of Wyeth until his retirement in March 2008. From 2008 until 2010, Mr. Corcoran was a member of the Board of Directors of AHI, Inc., a veterinary distribution company. From 2010 until 2016, Mr. Corcoran was a director of Putney, Inc., a pet pharmaceutical company. Mr. Corcoran also served as the Chairman of the Animal Health Institute, an indtry organization advocating for animal health issues, including efficient and effective FDA, DA and EPA regulatory and approval processes. Since 2009, Mr. Corcoran has served on the Board of Trtees of the University of South Alabama, where he is Chairman of the Finance and Budget committee.
- Joyce J. Lee
-
Joyce J. Lee自2012年10月起担任加拿大和拉丁美洲地区的执行副总裁兼区域总裁,并于2010年至2012年担任辉瑞动物保健的同一地区区域总裁。李女士于2003年加入辉瑞公司, 收购Pharmacia并担任辉瑞动物保健公司的全球家禽副总裁兼全球业务技术副总裁等多个职位。
Joyce J. Lee has been a director since January 2025. Ms. Lee most recently served as President of Cobb Vantress, LLC, a premier genetics company dedicated to feeding the world through responsible genetic innovation. Before joining Cobb Vantress, Ms. Lee held executive positions at Elanco, Bayer Animal Health, and Zoetis. Her extensive experience includes executive, global, regional, and country level leadership roles in publicly held companies. Ms. Lee has led diverse commercial and global functions throughout her career, including global genetics production, general management, strategy, sales, marketing, outcomes research, R&D, engineering, manufacturing, and information technology. Her significant contributions to the animal health indtry re recognized in 2018 when she received the prestigio Feather in Her Cap Award. Additionally, Ms. Lee has served as a board member on the corporate governance and nomination committee for over two years and on an audit committee for more than five years at a publicly traded company. Ms. Lee holds a Bachelor's Degree in Biness Administration from Baylor University and MBA in Healthcare Administration from Jackson University. - Joyce J. Lee自2012年10月起担任加拿大和拉丁美洲地区的执行副总裁兼区域总裁,并于2010年至2012年担任辉瑞动物保健的同一地区区域总裁。李女士于2003年加入辉瑞公司, 收购Pharmacia并担任辉瑞动物保健公司的全球家禽副总裁兼全球业务技术副总裁等多个职位。
- Joyce J. Lee has been a director since January 2025. Ms. Lee most recently served as President of Cobb Vantress, LLC, a premier genetics company dedicated to feeding the world through responsible genetic innovation. Before joining Cobb Vantress, Ms. Lee held executive positions at Elanco, Bayer Animal Health, and Zoetis. Her extensive experience includes executive, global, regional, and country level leadership roles in publicly held companies. Ms. Lee has led diverse commercial and global functions throughout her career, including global genetics production, general management, strategy, sales, marketing, outcomes research, R&D, engineering, manufacturing, and information technology. Her significant contributions to the animal health indtry re recognized in 2018 when she received the prestigio Feather in Her Cap Award. Additionally, Ms. Lee has served as a board member on the corporate governance and nomination committee for over two years and on an audit committee for more than five years at a publicly traded company. Ms. Lee holds a Bachelor's Degree in Biness Administration from Baylor University and MBA in Healthcare Administration from Jackson University.
- Carol A. Wrenn
-
Carol A. Wrenn自2013年1月担任董事。她在2010年创建了Sky River Helicopters,并自此担任总裁。从2001年到2009年,她担任Alpharma Inc.动物健康部门的执行副总裁和总裁。Wrenn女士从2007年到2009年还担任动物健康协会(Alpharma Inc.)主席,同时从2002年到2009年是国际动物健康联合会(Alpharma Inc.)董事会成员。在加入Alpharma药厂前,Wrenn女士从1984年到2001年在Honeywell International(原 AlliedSignal Inc)担任各种管理职务。她从2000年到2001年担任Honeywell International制冷剂和氟产品部门董事,同时从1997年到2000年担任Honeywell International欧洲氟化物部门商务总监和常务董事。Wrenn女士在AlliedSignal任职期间还在销售、市场营销、业务开发以及财务领域担任一些职务。Wrenn女士在Phibro Animal Health担任董事。她从联合学院(Union College)获得学士学位,从利哈伊大学(Lehigh University)获得工商管理学硕士学位。
Carol A. Wrenn has been a director since July 2010. Ms. Wrenn also serves as a member of the Audit Committee and the Compensation Committee. She is currently the sole owner of Aurora Borealis LLC, which operates online retail binesses. She was the founder and owner of Whitewater Advisors LLC, which provided consulting services to small binesses from 2017 through 2020. She was also the founder and owner of Sky River Helicopters, LLC, a company that provided helicopter charters, ts, commercial services, and lessons, from January 2010 until September 2015. She previoly served as an Executive Vice President and the President of the Animal Health Division at Alpharma Inc., a human and animal pharmaceutical company, from November 2001 to June 2009. From April 2007 to April 2009, Ms. Wrenn also held the position of Chairman of the Animal Health Institute, an indtry organization advocating for animal health issues, including efficient and effective FDA, DA and EPA regulatory and approval processes. - Carol A. Wrenn自2013年1月担任董事。她在2010年创建了Sky River Helicopters,并自此担任总裁。从2001年到2009年,她担任Alpharma Inc.动物健康部门的执行副总裁和总裁。Wrenn女士从2007年到2009年还担任动物健康协会(Alpharma Inc.)主席,同时从2002年到2009年是国际动物健康联合会(Alpharma Inc.)董事会成员。在加入Alpharma药厂前,Wrenn女士从1984年到2001年在Honeywell International(原 AlliedSignal Inc)担任各种管理职务。她从2000年到2001年担任Honeywell International制冷剂和氟产品部门董事,同时从1997年到2000年担任Honeywell International欧洲氟化物部门商务总监和常务董事。Wrenn女士在AlliedSignal任职期间还在销售、市场营销、业务开发以及财务领域担任一些职务。Wrenn女士在Phibro Animal Health担任董事。她从联合学院(Union College)获得学士学位,从利哈伊大学(Lehigh University)获得工商管理学硕士学位。
- Carol A. Wrenn has been a director since July 2010. Ms. Wrenn also serves as a member of the Audit Committee and the Compensation Committee. She is currently the sole owner of Aurora Borealis LLC, which operates online retail binesses. She was the founder and owner of Whitewater Advisors LLC, which provided consulting services to small binesses from 2017 through 2020. She was also the founder and owner of Sky River Helicopters, LLC, a company that provided helicopter charters, ts, commercial services, and lessons, from January 2010 until September 2015. She previoly served as an Executive Vice President and the President of the Animal Health Division at Alpharma Inc., a human and animal pharmaceutical company, from November 2001 to June 2009. From April 2007 to April 2009, Ms. Wrenn also held the position of Chairman of the Animal Health Institute, an indtry organization advocating for animal health issues, including efficient and effective FDA, DA and EPA regulatory and approval processes.
- Jack C. Bendheim
-
Jack C. Bendheim,董事会主席、总裁兼首席执行官。 Bendheim 先生自 1988 年起担任 Phibro Animal Health Corporation 总裁,并于 2014 年 3 月被任命为首席执行官。他自 1984 年起担任董事。Bendheim 先生还担任薪酬委员会成员。 Bendheim 先生于 1969 年加入 Phibro Animal Health Corporation,并于 1998 年至 2002 年担任首席执行官,1988 年至 1998 年担任首席运营官,1983 年至 1988 年担任执行副总裁兼财务主管,1975 年至 1983 年担任副总裁兼财务主管。直到2017 年,Bendheim 先生还担任 Empire Resources, Inc. 的董事会成员。Bendheim 先生还是动物健康研究所的前任主席,该研究所是一个倡导动物健康问题的行业组织,包括高效和有效的 FDA、USDA 和 EPA 监管和审批流程。 Bendheim 先生与某些其他家庭成员是 BFI 的经理,负责与 BFI 拥有的 Phibro Animal Health Corporation 股票有关的经济权利。 Bendheim 先生拥有对 BFI 拥有的 Phibro Animal Health Corporation 股票的投票权。 Bendheim 先生是 Daniel M. Bendheim 和 Jonathan Bendheim 的父亲。
Jack C. Bendheim is Chairman of Board of Directors and serves as President and Chief Executive Officer. Mr. Bendheim has served as President since 1988 and he was also appointed Chief Executive Officer in March 2014. He has been a director since 1984. Mr. Bendheim joined in 1969 and served as Chief Executive Officer from 1998 to 2002, as Chief Operating Officer from 1988 to 1998, as Executive Vice President and Treasurer from 1983 to 1988 and as Vice President and Treasurer from 1975 to 1983. Until 2017, Mr. Bendheim served on the Board of Directors of Empire Resces, Inc. Mr. Bendheim is also a past Chairman of the Animal Health Institute, an indtry organization advocating for animal health issues, including efficient and effective FDA, DA and EPA regulatory and approval processes. In March 2025, Mr. Bendheim was named as President of HealthforAnimals, a global animal health association. HealthforAnimals' members represent approximately 90% of the global market for veterinary pharmaceuticals, vaccines, diagnostics and other animal health products worldwide. Mr. Bendheim, together with certain other family members, is a manager of BFI Co., LLC ("BFI"), an investment vehicle of the Bendheim family, with respect to the economic rights pertaining to shares of stock owned by BFI. Mr. Bendheim has sole authority to vote shares of stock owned by BFI. - Jack C. Bendheim,董事会主席、总裁兼首席执行官。 Bendheim 先生自 1988 年起担任 Phibro Animal Health Corporation 总裁,并于 2014 年 3 月被任命为首席执行官。他自 1984 年起担任董事。Bendheim 先生还担任薪酬委员会成员。 Bendheim 先生于 1969 年加入 Phibro Animal Health Corporation,并于 1998 年至 2002 年担任首席执行官,1988 年至 1998 年担任首席运营官,1983 年至 1988 年担任执行副总裁兼财务主管,1975 年至 1983 年担任副总裁兼财务主管。直到2017 年,Bendheim 先生还担任 Empire Resources, Inc. 的董事会成员。Bendheim 先生还是动物健康研究所的前任主席,该研究所是一个倡导动物健康问题的行业组织,包括高效和有效的 FDA、USDA 和 EPA 监管和审批流程。 Bendheim 先生与某些其他家庭成员是 BFI 的经理,负责与 BFI 拥有的 Phibro Animal Health Corporation 股票有关的经济权利。 Bendheim 先生拥有对 BFI 拥有的 Phibro Animal Health Corporation 股票的投票权。 Bendheim 先生是 Daniel M. Bendheim 和 Jonathan Bendheim 的父亲。
- Jack C. Bendheim is Chairman of Board of Directors and serves as President and Chief Executive Officer. Mr. Bendheim has served as President since 1988 and he was also appointed Chief Executive Officer in March 2014. He has been a director since 1984. Mr. Bendheim joined in 1969 and served as Chief Executive Officer from 1998 to 2002, as Chief Operating Officer from 1988 to 1998, as Executive Vice President and Treasurer from 1983 to 1988 and as Vice President and Treasurer from 1975 to 1983. Until 2017, Mr. Bendheim served on the Board of Directors of Empire Resces, Inc. Mr. Bendheim is also a past Chairman of the Animal Health Institute, an indtry organization advocating for animal health issues, including efficient and effective FDA, DA and EPA regulatory and approval processes. In March 2025, Mr. Bendheim was named as President of HealthforAnimals, a global animal health association. HealthforAnimals' members represent approximately 90% of the global market for veterinary pharmaceuticals, vaccines, diagnostics and other animal health products worldwide. Mr. Bendheim, together with certain other family members, is a manager of BFI Co., LLC ("BFI"), an investment vehicle of the Bendheim family, with respect to the economic rights pertaining to shares of stock owned by BFI. Mr. Bendheim has sole authority to vote shares of stock owned by BFI.
- Daniel M. Bendheim
-
Daniel M. Bendheim,公司战略总监兼执行副总裁。Bendheim先生于1997年加入Phibro Animal Health Corporation。他于2001年被任命为业务发展副总裁,后来于2004年被任命为性能产品总裁,然后于2014年3月被任命为企业战略执行副总裁。2013年11月,他选为Phibro董事。在加入Phibro Animal Health Corporation之前,Bendheim先生曾在一家精品投资银行South Coast Capital担任分析师。Bendheim先生获得了学士学位。1993年获得叶史瓦大学政治学荣誉学位,1996年获得哈佛法学院法学博士荣誉学位。Bendheim先生是Jack C. Bendheim的儿子,与其他某些家庭成员一起,是BFI的经理,负责与BFI拥有的Phibro Animal Health Corporation股票有关的某些经济权利。
Daniel M. Bendheim serves as a member of Board of Directors and is Executive Vice President, Corporate Strategy. Mr. Bendheim joined in 1997. He was appointed Vice President of Biness Development in 2001 and was later appointed President, Performance Products in 2004, and then Executive Vice President, Corporate Strategy in March 2014. He was elected as a director of Phibro in November 2013. Prior to joining , Mr. Bendheim worked as an analyst at South Coast Capital, a boutique investment bank. Mr. Bendheim obtained a B.A. degree in political science with honors from Yeshiva University in 1993 and a J.D. degree with honors from Harvard Law School in 1996. Mr. Bendheim is a son of Jack C. Bendheim and, together with certain other family members, is a manager of BFI with respect to certain economic rights pertaining to shares of stock owned by BFI. - Daniel M. Bendheim,公司战略总监兼执行副总裁。Bendheim先生于1997年加入Phibro Animal Health Corporation。他于2001年被任命为业务发展副总裁,后来于2004年被任命为性能产品总裁,然后于2014年3月被任命为企业战略执行副总裁。2013年11月,他选为Phibro董事。在加入Phibro Animal Health Corporation之前,Bendheim先生曾在一家精品投资银行South Coast Capital担任分析师。Bendheim先生获得了学士学位。1993年获得叶史瓦大学政治学荣誉学位,1996年获得哈佛法学院法学博士荣誉学位。Bendheim先生是Jack C. Bendheim的儿子,与其他某些家庭成员一起,是BFI的经理,负责与BFI拥有的Phibro Animal Health Corporation股票有关的某些经济权利。
- Daniel M. Bendheim serves as a member of Board of Directors and is Executive Vice President, Corporate Strategy. Mr. Bendheim joined in 1997. He was appointed Vice President of Biness Development in 2001 and was later appointed President, Performance Products in 2004, and then Executive Vice President, Corporate Strategy in March 2014. He was elected as a director of Phibro in November 2013. Prior to joining , Mr. Bendheim worked as an analyst at South Coast Capital, a boutique investment bank. Mr. Bendheim obtained a B.A. degree in political science with honors from Yeshiva University in 1993 and a J.D. degree with honors from Harvard Law School in 1996. Mr. Bendheim is a son of Jack C. Bendheim and, together with certain other family members, is a manager of BFI with respect to certain economic rights pertaining to shares of stock owned by BFI.
- Sam Gejdenson
-
Sam Gejdenson 自 2004 年 1 月起担任 Phibro 的董事,并且是 Phibro Animal Health Corporation 的审计委员会和 Phibro Animal Health Corporation 的薪酬委员会的成员。 Gejdenson 先生是 Phibro Animal Health Corporation 薪酬委员会的主席。自 2001 年以来,Gejdenson 先生通过他自己的公司 Sam Gejdenson International 参与了国际贸易,在那里他与多个跨国客户合作处理欧洲、亚洲和非洲的项目。 Gejdenson 先生目前在国家民主研究所董事会任职,曾任美国国际宗教自由委员会委员。从 1981 年到 2001 年,Gejdenson 先生在康涅狄格州东部担任美国众议院国会议员,在那里他是众议院国际关系委员会的高级民主党人。 In 1974 he was elected to the Connecticut House of Representatives, serving two terms。他获得了 A.S。 1968 年在康涅狄格州新伦敦的米切尔学院获得学位,并获得学士学位。 1970 年毕业于康涅狄格州斯托斯的康涅狄格大学。
Sam Gejdenson has been a director of Phibro since January 2004 and is a member of Audit Committee and Compensation Committee. Mr. Gejdenson is the Chair of Compensation Committee. Since 2001, Mr. Gejdenson has been involved in international trade through his own company, Sam Gejdenson International, where he has worked with vario multi national clients on projects in Europe, Asia and Africa. Mr. Gejdenson presently serves on the board of the National Democratic Institute and was formerly a Commissioner on the U.S. Commission for International Religio Freedom. From 1981 to 2001, Mr. Gejdenson served eastern Connecticut as a Congressman in the U.S. Hoe of Representatives where he was the senior Democrat on the Hoe International Relations Committee. In 1974, he was elected to the Connecticut Hoe of Representatives, serving two terms. He received an A.S. degree from Mitchell College in New London, Connecticut in 1968 and a B.A. from the University of Connecticut in Storrs, Connecticut in 1970. - Sam Gejdenson 自 2004 年 1 月起担任 Phibro 的董事,并且是 Phibro Animal Health Corporation 的审计委员会和 Phibro Animal Health Corporation 的薪酬委员会的成员。 Gejdenson 先生是 Phibro Animal Health Corporation 薪酬委员会的主席。自 2001 年以来,Gejdenson 先生通过他自己的公司 Sam Gejdenson International 参与了国际贸易,在那里他与多个跨国客户合作处理欧洲、亚洲和非洲的项目。 Gejdenson 先生目前在国家民主研究所董事会任职,曾任美国国际宗教自由委员会委员。从 1981 年到 2001 年,Gejdenson 先生在康涅狄格州东部担任美国众议院国会议员,在那里他是众议院国际关系委员会的高级民主党人。 In 1974 he was elected to the Connecticut House of Representatives, serving two terms。他获得了 A.S。 1968 年在康涅狄格州新伦敦的米切尔学院获得学位,并获得学士学位。 1970 年毕业于康涅狄格州斯托斯的康涅狄格大学。
- Sam Gejdenson has been a director of Phibro since January 2004 and is a member of Audit Committee and Compensation Committee. Mr. Gejdenson is the Chair of Compensation Committee. Since 2001, Mr. Gejdenson has been involved in international trade through his own company, Sam Gejdenson International, where he has worked with vario multi national clients on projects in Europe, Asia and Africa. Mr. Gejdenson presently serves on the board of the National Democratic Institute and was formerly a Commissioner on the U.S. Commission for International Religio Freedom. From 1981 to 2001, Mr. Gejdenson served eastern Connecticut as a Congressman in the U.S. Hoe of Representatives where he was the senior Democrat on the Hoe International Relations Committee. In 1974, he was elected to the Connecticut Hoe of Representatives, serving two terms. He received an A.S. degree from Mitchell College in New London, Connecticut in 1968 and a B.A. from the University of Connecticut in Storrs, Connecticut in 1970.
- Mary Lou Malanoski
-
Mary Lou Malanoski自2004年5月起担任董事。Malanoski女士是S2K Partners Co. LLC的首席财务官,并于2016年4月开始担任其前身实体S2K Financial Holdings LLC和S2K Partners Holdings LLC的首席财务官。此前,Malanoski女士于2015年4月至2016年3月担任独立财务顾问,并于2015年6月至2015年12月担任Nina McLemore,LLC的代理首席财务官。2012年3月至2015年3月,Malanoski女士担任Morgan Joseph TriArtisan Group,Inc.的副主席兼首席运营官,Morgan Joseph TriArtisan Group,Inc是一家专注于中端市场公司的投资银行。她于2001年7月加入Morgan Joseph TriArtisan Group,Inc.,担任董事总经理兼首席财务官,2008年成为投资银行业务联席主管,并于2009年3月至2012年3月担任投资银行业务主管。Malanoski女士还在2008年至2021年期间担任Morgan Joseph TriArtisan Group,Inc.的董事会成员。从1994年到2001年,Malanoski女士担任她共同创立的私募股权公司New Street Advisors LP的董事总经理兼首席财务官。在1994年之前,Malanoski女士是New Street Capital的董事总经理,New Street Capital是重组后的Drexel Burnham Lambert的继任者,在那里她开始了她在企业财务部的职业生涯。Malanoski女士是Getty Realty Corp.的董事会成员,也是审计委员会和提名/公司治理委员会的成员,Getty Realty Corp.是一家专门从事便利店、加油站和相关物业的房地产投资信托公司。
Mary Lou Malanoski has been a director since May 2004. Ms. Malanoski is the Chief Financial Officer of S2K Partners Co. LLC and was the Chief Financial Officer of its predecessor entities, S2K Financial Holdings LLC and S2K Partners Holdings LLC, beginning in April 2016. - Mary Lou Malanoski自2004年5月起担任董事。Malanoski女士是S2K Partners Co. LLC的首席财务官,并于2016年4月开始担任其前身实体S2K Financial Holdings LLC和S2K Partners Holdings LLC的首席财务官。此前,Malanoski女士于2015年4月至2016年3月担任独立财务顾问,并于2015年6月至2015年12月担任Nina McLemore,LLC的代理首席财务官。2012年3月至2015年3月,Malanoski女士担任Morgan Joseph TriArtisan Group,Inc.的副主席兼首席运营官,Morgan Joseph TriArtisan Group,Inc是一家专注于中端市场公司的投资银行。她于2001年7月加入Morgan Joseph TriArtisan Group,Inc.,担任董事总经理兼首席财务官,2008年成为投资银行业务联席主管,并于2009年3月至2012年3月担任投资银行业务主管。Malanoski女士还在2008年至2021年期间担任Morgan Joseph TriArtisan Group,Inc.的董事会成员。从1994年到2001年,Malanoski女士担任她共同创立的私募股权公司New Street Advisors LP的董事总经理兼首席财务官。在1994年之前,Malanoski女士是New Street Capital的董事总经理,New Street Capital是重组后的Drexel Burnham Lambert的继任者,在那里她开始了她在企业财务部的职业生涯。Malanoski女士是Getty Realty Corp.的董事会成员,也是审计委员会和提名/公司治理委员会的成员,Getty Realty Corp.是一家专门从事便利店、加油站和相关物业的房地产投资信托公司。
- Mary Lou Malanoski has been a director since May 2004. Ms. Malanoski is the Chief Financial Officer of S2K Partners Co. LLC and was the Chief Financial Officer of its predecessor entities, S2K Financial Holdings LLC and S2K Partners Holdings LLC, beginning in April 2016.
高管简历
中英对照 |  中文 |  英文- Lisa A. Escudero
LisaA.Escudero,高级副总裁,人力资源。Escudero女士于2017年3月加入我们,担任现任职务。2016年至2017年,她担任非营利生物医学研究组织纽约基因组中心(英语:New York Genome Center)的人力资源Vice President。加入NYGC公司之前,她曾领导American Standard Brands公司(管道设备制造商)的人力资源职能(2008年至2016年),在那里她曾担任领导团队成员。从1990年到2008年,她曾担任Merck&Co.(全球领先的制药公司)的人力资源董事,在那里她曾支持研究和制造部门。在默克公司任职之前,Escudero女士于1982年至1990年担任化学制造公司FMC Corporation农业化学集团的研究科学家。她持有Rutgers University的心理学学士学位,以及the Rutgers University School of Management&Labor Relations的人力资源管理硕士学位。
Lisa A. Escudero joined in her current role in March 2017. From 2016 to 2017, she was Vice President of Human Resces for the New York Genome Center, a nonprofit biomedical research organization, where she led the human resces function. Prior to joining NYGC, she led the HR function for American Standard Brands, a plumbing fixture manufacturer, from 2008 to 2016, where she was a member of the leadership team. From 1990 to 2008, Ms. Escudero was Director of Human Resces for Merck & Co., a leading global pharmaceutical company, where she supported the research and manufacturing divisions. Prior to her role at Merck, Ms. Escudero was a research scientist for the Agricultural Chemical Group of FMC Corporation, a chemical manufacturing company, from 1982 to 1990. She holds a B.A. degree in Psychology from Rutgers University and an M.S. degree in Human Resces Management from the Rutgers University School of Management & Labor Relations.- LisaA.Escudero,高级副总裁,人力资源。Escudero女士于2017年3月加入我们,担任现任职务。2016年至2017年,她担任非营利生物医学研究组织纽约基因组中心(英语:New York Genome Center)的人力资源Vice President。加入NYGC公司之前,她曾领导American Standard Brands公司(管道设备制造商)的人力资源职能(2008年至2016年),在那里她曾担任领导团队成员。从1990年到2008年,她曾担任Merck&Co.(全球领先的制药公司)的人力资源董事,在那里她曾支持研究和制造部门。在默克公司任职之前,Escudero女士于1982年至1990年担任化学制造公司FMC Corporation农业化学集团的研究科学家。她持有Rutgers University的心理学学士学位,以及the Rutgers University School of Management&Labor Relations的人力资源管理硕士学位。
- Lisa A. Escudero joined in her current role in March 2017. From 2016 to 2017, she was Vice President of Human Resces for the New York Genome Center, a nonprofit biomedical research organization, where she led the human resces function. Prior to joining NYGC, she led the HR function for American Standard Brands, a plumbing fixture manufacturer, from 2008 to 2016, where she was a member of the leadership team. From 1990 to 2008, Ms. Escudero was Director of Human Resces for Merck & Co., a leading global pharmaceutical company, where she supported the research and manufacturing divisions. Prior to her role at Merck, Ms. Escudero was a research scientist for the Agricultural Chemical Group of FMC Corporation, a chemical manufacturing company, from 1982 to 1990. She holds a B.A. degree in Psychology from Rutgers University and an M.S. degree in Human Resces Management from the Rutgers University School of Management & Labor Relations.
- Anthony Andolino
Anthony Andolino,Vice President财务和司库。Andolino先生于2011年10月加入我们,担任公司,乙醇性能集团和Phibrochem部门的财务总监。他于2018年3月晋升为Vice President、财务主管和财务主管。从2009年到2011年,他曾担任Huntington Learning Centers公司(教育服务中心)的总会计师。Andolino从2007年到2008年担任Mezz Cap(一家金融管理服务公司)助理财务总监。任职Mezz Cap公司之前,Andolino曾担任Mercer Human Resources Consulting公司的财务总监兼董事(2004年至2007年)。Andolino从1991年到2004年在JD Edwards World Solution Company,The Mony Group和Deloitte&Touche担任多个财务总监和金融职位。他持有Pace University的公共会计B.B.A.学位。他是新泽西州有执照的注册会计师。
Anthony Andolino joined in October 2011 as Controller, Corporate, Ethanol Performance Group and PhibroChem Divisions. He was promoted to Vice President, Finance and Treasurer in March 2018. From 2009 to 2011 he was Controller at Huntington Learning Centers, an educational service center. From 2007 to 2008, Mr. Andolino was an Assistant Controller at Mezz Cap, a financial management service company. Prior to his role at Mezz Cap, Mr. Andolino was a Controller and Director of Finance for Mercer Human Resces Consulting from 2004 to 2007. From 1991 to 2004, Mr. Andolino held vario controller and finance positions at JD Edwards World Solution Company, The MONY Group and Deloitte & Touche. He holds a B.B.A. degree in Public Accounting from Pace University. He is a licensed Certified Public Accountant in the State of New Jersey.- Anthony Andolino,Vice President财务和司库。Andolino先生于2011年10月加入我们,担任公司,乙醇性能集团和Phibrochem部门的财务总监。他于2018年3月晋升为Vice President、财务主管和财务主管。从2009年到2011年,他曾担任Huntington Learning Centers公司(教育服务中心)的总会计师。Andolino从2007年到2008年担任Mezz Cap(一家金融管理服务公司)助理财务总监。任职Mezz Cap公司之前,Andolino曾担任Mercer Human Resources Consulting公司的财务总监兼董事(2004年至2007年)。Andolino从1991年到2004年在JD Edwards World Solution Company,The Mony Group和Deloitte&Touche担任多个财务总监和金融职位。他持有Pace University的公共会计B.B.A.学位。他是新泽西州有执照的注册会计师。
- Anthony Andolino joined in October 2011 as Controller, Corporate, Ethanol Performance Group and PhibroChem Divisions. He was promoted to Vice President, Finance and Treasurer in March 2018. From 2009 to 2011 he was Controller at Huntington Learning Centers, an educational service center. From 2007 to 2008, Mr. Andolino was an Assistant Controller at Mezz Cap, a financial management service company. Prior to his role at Mezz Cap, Mr. Andolino was a Controller and Director of Finance for Mercer Human Resces Consulting from 2004 to 2007. From 1991 to 2004, Mr. Andolino held vario controller and finance positions at JD Edwards World Solution Company, The MONY Group and Deloitte & Touche. He holds a B.B.A. degree in Public Accounting from Pace University. He is a licensed Certified Public Accountant in the State of New Jersey.
- Jonathan Bendheim
Jonathan Bendheim是我们的董事会成员,是我们Macie地区的总裁,Macie地区包括中东、非洲、独立国家联合体、印度和欧洲,他是我们在以色列和爱尔兰运营工厂的总经理,并监管Phibro’;的全球水产养殖业务。Bendheim先生于2001年加入Phibro,担任物流和供应链经理。2005年,本德海姆先生被任命为我们以色列业务的销售和业务发展Vice President。2008年他领导从Teva收购ABIC Biological Laboratories,2009年他被任命为我们在以色列运营的董事总经理。2011年,他的职责扩大到包括监督Macie地区的所有销售活动。本德海姆先生于2014年领导成立了Phibro&8217;s全球水产养殖业务,并于2018年创立了Phibro&8217;s PHI-Tech业务部门。Mr.Bendheim持有Yeshiva University政治学学士学位和Columbia Business School工商管理硕士学位。本德海姆先生是JackC.Bendheim的儿子
Jonathan Bendheim serves as a member of Board of Directors and was appointed to the role of Senior Vice President, Global Technology and Talent in September 2024. Previoly, Mr. Bendheim served as President of MACIE Region (which consists of the Middle East, Africa, the Commonalth of Independent States, India and Europe) and was the general manager of operating plants in Israel and Ireland. Mr. Bendheim will continue to oversee his commercial responsibilities as head of the MACIE region until a successor is appointed. Mr. Bendheim will retain operational responsibility for MACIE manufacturing and R&D operations, and Phibro's global aquaculture biness. Mr. Bendheim joined Phibro in 2001 as a Manager for logistics and supply chain. In 2005, Mr. Bendheim was appointed Vice President of Sales and Biness Development for Israel operations. In 2008, he led the acquisition of Abic Biological Laboratories from Teva, and in 2009, he was appointed the Managing Director of operations in Israel. In 2011, his responsibilities re expanded to include oversight of all sales activities in the MACIE Region. Mr. Bendheim led the establishment of Phibro's global aquaculture biness in 2014. Mr. Bendheim holds a B.A. degree in political science from Yeshiva University and an MBA from Columbia Biness School.- Jonathan Bendheim是我们的董事会成员,是我们Macie地区的总裁,Macie地区包括中东、非洲、独立国家联合体、印度和欧洲,他是我们在以色列和爱尔兰运营工厂的总经理,并监管Phibro’;的全球水产养殖业务。Bendheim先生于2001年加入Phibro,担任物流和供应链经理。2005年,本德海姆先生被任命为我们以色列业务的销售和业务发展Vice President。2008年他领导从Teva收购ABIC Biological Laboratories,2009年他被任命为我们在以色列运营的董事总经理。2011年,他的职责扩大到包括监督Macie地区的所有销售活动。本德海姆先生于2014年领导成立了Phibro&8217;s全球水产养殖业务,并于2018年创立了Phibro&8217;s PHI-Tech业务部门。Mr.Bendheim持有Yeshiva University政治学学士学位和Columbia Business School工商管理硕士学位。本德海姆先生是JackC.Bendheim的儿子
- Jonathan Bendheim serves as a member of Board of Directors and was appointed to the role of Senior Vice President, Global Technology and Talent in September 2024. Previoly, Mr. Bendheim served as President of MACIE Region (which consists of the Middle East, Africa, the Commonalth of Independent States, India and Europe) and was the general manager of operating plants in Israel and Ireland. Mr. Bendheim will continue to oversee his commercial responsibilities as head of the MACIE region until a successor is appointed. Mr. Bendheim will retain operational responsibility for MACIE manufacturing and R&D operations, and Phibro's global aquaculture biness. Mr. Bendheim joined Phibro in 2001 as a Manager for logistics and supply chain. In 2005, Mr. Bendheim was appointed Vice President of Sales and Biness Development for Israel operations. In 2008, he led the acquisition of Abic Biological Laboratories from Teva, and in 2009, he was appointed the Managing Director of operations in Israel. In 2011, his responsibilities re expanded to include oversight of all sales activities in the MACIE Region. Mr. Bendheim led the establishment of Phibro's global aquaculture biness in 2014. Mr. Bendheim holds a B.A. degree in political science from Yeshiva University and an MBA from Columbia Biness School.
- Judith A. Weinstein
Judith A. Weinstein,2008年加入Phibro,担任副总法律顾问。她于2017年晋升为法务副总裁,在Phibro拥有超过15年的工作经验,并于2023年7月1日晋升为高级副总裁、总法律顾问和公司秘书。在加入Phibro之前,韦恩斯坦曾在全球知名的制药、食品、医疗器械和化妆品公司担任多个法律职位。韦恩斯坦女士曾在诺华公司的消费者健康部门担任格柏产品公司的协理总法律顾问,负责全球法律问题,并在格柏执行管理团队任职。此外,韦恩斯坦女士还曾担任辉瑞公司的高级公司法律顾问,负责Celebrex 的法律事务,并担任Elizabeth Arden, Inc.的助理总法律顾问。在她职业生涯的早期,韦恩斯坦女士是Burditt & Radzius,Chartered律师事务所的助理,这是一家专门从事食品和药品法律的律师事务所。韦恩斯坦女士在威斯康星大学麦迪逊分校获得学士学位,在芝加哥-肯特法学院(隶属于伊利诺伊理工学院)获得法学博士学位,并担任学生律师协会主席。
Judith A. Weinstein joined Phibro as Associate General Counsel in 2008. She was promoted to Vice President, Legal in 2017 and with more than 15 years of experience at Phibro, was promoted to Senior Vice President, General Counsel and Corporate Secretary as of July 1, 2023. Prior to joining Phibro, Ms. instein held vario legal positions at globally recognized companies foced on pharmaceuticals, food, medical devices, and cosmetics. Ms. instein worked at Novartis AG in the consumer health division as Associate General Counsel for the Gerber Products Company, where she was responsible for global legal issues and served on the Gerber Executive Management Team.Ms. instein obtained her B.S. degree from the University of Wisconsin Madison and her J.D. degree from Chicago Kent College of Law (part of the Illinois Institute of Technology), where she served as President of the Student Bar Association.- Judith A. Weinstein,2008年加入Phibro,担任副总法律顾问。她于2017年晋升为法务副总裁,在Phibro拥有超过15年的工作经验,并于2023年7月1日晋升为高级副总裁、总法律顾问和公司秘书。在加入Phibro之前,韦恩斯坦曾在全球知名的制药、食品、医疗器械和化妆品公司担任多个法律职位。韦恩斯坦女士曾在诺华公司的消费者健康部门担任格柏产品公司的协理总法律顾问,负责全球法律问题,并在格柏执行管理团队任职。此外,韦恩斯坦女士还曾担任辉瑞公司的高级公司法律顾问,负责Celebrex 的法律事务,并担任Elizabeth Arden, Inc.的助理总法律顾问。在她职业生涯的早期,韦恩斯坦女士是Burditt & Radzius,Chartered律师事务所的助理,这是一家专门从事食品和药品法律的律师事务所。韦恩斯坦女士在威斯康星大学麦迪逊分校获得学士学位,在芝加哥-肯特法学院(隶属于伊利诺伊理工学院)获得法学博士学位,并担任学生律师协会主席。
- Judith A. Weinstein joined Phibro as Associate General Counsel in 2008. She was promoted to Vice President, Legal in 2017 and with more than 15 years of experience at Phibro, was promoted to Senior Vice President, General Counsel and Corporate Secretary as of July 1, 2023. Prior to joining Phibro, Ms. instein held vario legal positions at globally recognized companies foced on pharmaceuticals, food, medical devices, and cosmetics. Ms. instein worked at Novartis AG in the consumer health division as Associate General Counsel for the Gerber Products Company, where she was responsible for global legal issues and served on the Gerber Executive Management Team.Ms. instein obtained her B.S. degree from the University of Wisconsin Madison and her J.D. degree from Chicago Kent College of Law (part of the Illinois Institute of Technology), where she served as President of the Student Bar Association.
- Glenn David
Glenn David自2024年2月起担任首席财务官职务。David先生带来了30多年的商业和金融领导角色经验。在加入之前,David先生于2022年11月至2023年2月在硕腾公司担任执行副总裁兼运营、诊断、生物设备和保险业务集团总裁。在此之前,2021年8月至2022年11月,他在硕腾担任执行副总裁兼集团总裁,负责国际运营、水产养殖、生物设备和保险。David先生于2016年至2021年期间担任硕腾的首席财务官,在该公司保持着资本化且财务纪律严明的BINEY,为股东创造了重大价值,在其职业生涯的早期,他曾在硕腾于2013年首次公开发行股票期间担任财务运营高级副总裁。在硕腾首次公开募股之前,David先生曾在辉瑞公司担任过多个财务职务,包括辉瑞动物保健国际的全球财务副总裁和美国初级保健专营权的财务副总裁。David先生在宾厄姆顿大学获得金融学学士学位,在纽约大学斯特恩比尼斯学院获得金融/IT硕士学位。
Glenn David has served as Chief Financial Officer since February 2024. Mr. David has over 30 years of experience in commercial and financial leadership roles. Prior to joining , Mr. David was Executive Vice President and Group President, Operations, Diagnostics, Biodevices and Insurance at Zoetis Inc. from November 2022 to February 2023. Prior to that, from Augt 2021 to November 2022, he served as Executive Vice President and Group President, International Operations, Aquaculture, Biodevices and Insurance at Zoetis. Mr. David was the Chief Financial Officer at Zoetis from 2016 to 2021, where he maintained a ll capitalized and financially disciplined biness, creating significant value for shareholders and earlier in his career, he served as Senior Vice President of Finance Operations for Zoetis during its Initial Public Offering in 2013. Before the Zoetis IPO, Mr. David served in vario financial roles at Pfizer Inc., including Vice President of Global Finance for Pfizer Animal Health and Vice President of Finance for the U.S. Primary Care franchise. Mr. David earned his B.S. degree in Finance from Binghamton University and his M.B.A. in Finance/IT from New York University Stern School of Biness.- Glenn David自2024年2月起担任首席财务官职务。David先生带来了30多年的商业和金融领导角色经验。在加入之前,David先生于2022年11月至2023年2月在硕腾公司担任执行副总裁兼运营、诊断、生物设备和保险业务集团总裁。在此之前,2021年8月至2022年11月,他在硕腾担任执行副总裁兼集团总裁,负责国际运营、水产养殖、生物设备和保险。David先生于2016年至2021年期间担任硕腾的首席财务官,在该公司保持着资本化且财务纪律严明的BINEY,为股东创造了重大价值,在其职业生涯的早期,他曾在硕腾于2013年首次公开发行股票期间担任财务运营高级副总裁。在硕腾首次公开募股之前,David先生曾在辉瑞公司担任过多个财务职务,包括辉瑞动物保健国际的全球财务副总裁和美国初级保健专营权的财务副总裁。David先生在宾厄姆顿大学获得金融学学士学位,在纽约大学斯特恩比尼斯学院获得金融/IT硕士学位。
- Glenn David has served as Chief Financial Officer since February 2024. Mr. David has over 30 years of experience in commercial and financial leadership roles. Prior to joining , Mr. David was Executive Vice President and Group President, Operations, Diagnostics, Biodevices and Insurance at Zoetis Inc. from November 2022 to February 2023. Prior to that, from Augt 2021 to November 2022, he served as Executive Vice President and Group President, International Operations, Aquaculture, Biodevices and Insurance at Zoetis. Mr. David was the Chief Financial Officer at Zoetis from 2016 to 2021, where he maintained a ll capitalized and financially disciplined biness, creating significant value for shareholders and earlier in his career, he served as Senior Vice President of Finance Operations for Zoetis during its Initial Public Offering in 2013. Before the Zoetis IPO, Mr. David served in vario financial roles at Pfizer Inc., including Vice President of Global Finance for Pfizer Animal Health and Vice President of Finance for the U.S. Primary Care franchise. Mr. David earned his B.S. degree in Finance from Binghamton University and his M.B.A. in Finance/IT from New York University Stern School of Biness.
- Jack C. Bendheim
Jack C. Bendheim,董事会主席、总裁兼首席执行官。 Bendheim 先生自 1988 年起担任 Phibro Animal Health Corporation 总裁,并于 2014 年 3 月被任命为首席执行官。他自 1984 年起担任董事。Bendheim 先生还担任薪酬委员会成员。 Bendheim 先生于 1969 年加入 Phibro Animal Health Corporation,并于 1998 年至 2002 年担任首席执行官,1988 年至 1998 年担任首席运营官,1983 年至 1988 年担任执行副总裁兼财务主管,1975 年至 1983 年担任副总裁兼财务主管。直到2017 年,Bendheim 先生还担任 Empire Resources, Inc. 的董事会成员。Bendheim 先生还是动物健康研究所的前任主席,该研究所是一个倡导动物健康问题的行业组织,包括高效和有效的 FDA、USDA 和 EPA 监管和审批流程。 Bendheim 先生与某些其他家庭成员是 BFI 的经理,负责与 BFI 拥有的 Phibro Animal Health Corporation 股票有关的经济权利。 Bendheim 先生拥有对 BFI 拥有的 Phibro Animal Health Corporation 股票的投票权。 Bendheim 先生是 Daniel M. Bendheim 和 Jonathan Bendheim 的父亲。
Jack C. Bendheim is Chairman of Board of Directors and serves as President and Chief Executive Officer. Mr. Bendheim has served as President since 1988 and he was also appointed Chief Executive Officer in March 2014. He has been a director since 1984. Mr. Bendheim joined in 1969 and served as Chief Executive Officer from 1998 to 2002, as Chief Operating Officer from 1988 to 1998, as Executive Vice President and Treasurer from 1983 to 1988 and as Vice President and Treasurer from 1975 to 1983. Until 2017, Mr. Bendheim served on the Board of Directors of Empire Resces, Inc. Mr. Bendheim is also a past Chairman of the Animal Health Institute, an indtry organization advocating for animal health issues, including efficient and effective FDA, DA and EPA regulatory and approval processes. In March 2025, Mr. Bendheim was named as President of HealthforAnimals, a global animal health association. HealthforAnimals' members represent approximately 90% of the global market for veterinary pharmaceuticals, vaccines, diagnostics and other animal health products worldwide. Mr. Bendheim, together with certain other family members, is a manager of BFI Co., LLC ("BFI"), an investment vehicle of the Bendheim family, with respect to the economic rights pertaining to shares of stock owned by BFI. Mr. Bendheim has sole authority to vote shares of stock owned by BFI.- Jack C. Bendheim,董事会主席、总裁兼首席执行官。 Bendheim 先生自 1988 年起担任 Phibro Animal Health Corporation 总裁,并于 2014 年 3 月被任命为首席执行官。他自 1984 年起担任董事。Bendheim 先生还担任薪酬委员会成员。 Bendheim 先生于 1969 年加入 Phibro Animal Health Corporation,并于 1998 年至 2002 年担任首席执行官,1988 年至 1998 年担任首席运营官,1983 年至 1988 年担任执行副总裁兼财务主管,1975 年至 1983 年担任副总裁兼财务主管。直到2017 年,Bendheim 先生还担任 Empire Resources, Inc. 的董事会成员。Bendheim 先生还是动物健康研究所的前任主席,该研究所是一个倡导动物健康问题的行业组织,包括高效和有效的 FDA、USDA 和 EPA 监管和审批流程。 Bendheim 先生与某些其他家庭成员是 BFI 的经理,负责与 BFI 拥有的 Phibro Animal Health Corporation 股票有关的经济权利。 Bendheim 先生拥有对 BFI 拥有的 Phibro Animal Health Corporation 股票的投票权。 Bendheim 先生是 Daniel M. Bendheim 和 Jonathan Bendheim 的父亲。
- Jack C. Bendheim is Chairman of Board of Directors and serves as President and Chief Executive Officer. Mr. Bendheim has served as President since 1988 and he was also appointed Chief Executive Officer in March 2014. He has been a director since 1984. Mr. Bendheim joined in 1969 and served as Chief Executive Officer from 1998 to 2002, as Chief Operating Officer from 1988 to 1998, as Executive Vice President and Treasurer from 1983 to 1988 and as Vice President and Treasurer from 1975 to 1983. Until 2017, Mr. Bendheim served on the Board of Directors of Empire Resces, Inc. Mr. Bendheim is also a past Chairman of the Animal Health Institute, an indtry organization advocating for animal health issues, including efficient and effective FDA, DA and EPA regulatory and approval processes. In March 2025, Mr. Bendheim was named as President of HealthforAnimals, a global animal health association. HealthforAnimals' members represent approximately 90% of the global market for veterinary pharmaceuticals, vaccines, diagnostics and other animal health products worldwide. Mr. Bendheim, together with certain other family members, is a manager of BFI Co., LLC ("BFI"), an investment vehicle of the Bendheim family, with respect to the economic rights pertaining to shares of stock owned by BFI. Mr. Bendheim has sole authority to vote shares of stock owned by BFI.
- Daniel M. Bendheim
Daniel M. Bendheim,公司战略总监兼执行副总裁。Bendheim先生于1997年加入Phibro Animal Health Corporation。他于2001年被任命为业务发展副总裁,后来于2004年被任命为性能产品总裁,然后于2014年3月被任命为企业战略执行副总裁。2013年11月,他选为Phibro董事。在加入Phibro Animal Health Corporation之前,Bendheim先生曾在一家精品投资银行South Coast Capital担任分析师。Bendheim先生获得了学士学位。1993年获得叶史瓦大学政治学荣誉学位,1996年获得哈佛法学院法学博士荣誉学位。Bendheim先生是Jack C. Bendheim的儿子,与其他某些家庭成员一起,是BFI的经理,负责与BFI拥有的Phibro Animal Health Corporation股票有关的某些经济权利。
Daniel M. Bendheim serves as a member of Board of Directors and is Executive Vice President, Corporate Strategy. Mr. Bendheim joined in 1997. He was appointed Vice President of Biness Development in 2001 and was later appointed President, Performance Products in 2004, and then Executive Vice President, Corporate Strategy in March 2014. He was elected as a director of Phibro in November 2013. Prior to joining , Mr. Bendheim worked as an analyst at South Coast Capital, a boutique investment bank. Mr. Bendheim obtained a B.A. degree in political science with honors from Yeshiva University in 1993 and a J.D. degree with honors from Harvard Law School in 1996. Mr. Bendheim is a son of Jack C. Bendheim and, together with certain other family members, is a manager of BFI with respect to certain economic rights pertaining to shares of stock owned by BFI.- Daniel M. Bendheim,公司战略总监兼执行副总裁。Bendheim先生于1997年加入Phibro Animal Health Corporation。他于2001年被任命为业务发展副总裁,后来于2004年被任命为性能产品总裁,然后于2014年3月被任命为企业战略执行副总裁。2013年11月,他选为Phibro董事。在加入Phibro Animal Health Corporation之前,Bendheim先生曾在一家精品投资银行South Coast Capital担任分析师。Bendheim先生获得了学士学位。1993年获得叶史瓦大学政治学荣誉学位,1996年获得哈佛法学院法学博士荣誉学位。Bendheim先生是Jack C. Bendheim的儿子,与其他某些家庭成员一起,是BFI的经理,负责与BFI拥有的Phibro Animal Health Corporation股票有关的某些经济权利。
- Daniel M. Bendheim serves as a member of Board of Directors and is Executive Vice President, Corporate Strategy. Mr. Bendheim joined in 1997. He was appointed Vice President of Biness Development in 2001 and was later appointed President, Performance Products in 2004, and then Executive Vice President, Corporate Strategy in March 2014. He was elected as a director of Phibro in November 2013. Prior to joining , Mr. Bendheim worked as an analyst at South Coast Capital, a boutique investment bank. Mr. Bendheim obtained a B.A. degree in political science with honors from Yeshiva University in 1993 and a J.D. degree with honors from Harvard Law School in 1996. Mr. Bendheim is a son of Jack C. Bendheim and, together with certain other family members, is a manager of BFI with respect to certain economic rights pertaining to shares of stock owned by BFI.
- Larry L. Miller
Larry L. Miller自2010年12月31日以来担任董事。他在2002年退休(担任Utilicorp United, Inc.业务单元的首席执行官之后,负责公司发电和电力以及天然气传输和分销业务,服务于七个中大陆的130万个客户)。Utilicorp在纽约证券交易所(New York Stock Exchange)交易,2002年该公司更名为Aquila。2007年Utilicorp在密苏里州西北部的电力资产被Great Plains Energy Incorporated(NYSE:GXP)收购17亿美元,其天然气财产和其他资产被Black Hills Corporation(NYSE:BKH)收购9.4亿美元。他于1989年加入Utilicorp(通过收购Michigan Gas Utilities),从1983年到1991年担任总裁。他是Guardian 8 Holdings的董事会成员。他目前是The Nature Conservancy, Missouri Chapter的的主席,在过去的12年里他一直是理事。
Larry L. Miller has served as Chief Operating Officer since July 1, 2016. Mr. Miller joined as President, Animal Health in May 2008. Prior to joining , Mr. Miller was, from 2004 to 2008, Vice President of the Global Ruminant Biness with Intervet/Schering Plough Animal Health, which at that time was the largest animal health ruminant biness in the world. From 1998 to 2004, Mr. Miller was General Manager for Schering Plough's Atralia and New Zealand animal health binesses, which included a diversified portfolio of animal health and nutrition products for beef and dairy cattle, sheep, swine, poultry and companion animals. Mr. Miller held numero roles in sales and marketing management during his 17 years with Schering Plough, and prior to that with American Cyanamid Animal Health and Nutrition. He holds a B.S. degree in Animal Science from the University of Nebraska and an Executive MBA degree from the City University of New York. Mr. Miller is a member of the board of trtees of the University of Nebraska Foundation where he also serves on the Finance Committee and is also a member of the board of directors of the Nebraska Innovation Camp Development Corporation of the University of Nebraska Lincoln.- Larry L. Miller自2010年12月31日以来担任董事。他在2002年退休(担任Utilicorp United, Inc.业务单元的首席执行官之后,负责公司发电和电力以及天然气传输和分销业务,服务于七个中大陆的130万个客户)。Utilicorp在纽约证券交易所(New York Stock Exchange)交易,2002年该公司更名为Aquila。2007年Utilicorp在密苏里州西北部的电力资产被Great Plains Energy Incorporated(NYSE:GXP)收购17亿美元,其天然气财产和其他资产被Black Hills Corporation(NYSE:BKH)收购9.4亿美元。他于1989年加入Utilicorp(通过收购Michigan Gas Utilities),从1983年到1991年担任总裁。他是Guardian 8 Holdings的董事会成员。他目前是The Nature Conservancy, Missouri Chapter的的主席,在过去的12年里他一直是理事。
- Larry L. Miller has served as Chief Operating Officer since July 1, 2016. Mr. Miller joined as President, Animal Health in May 2008. Prior to joining , Mr. Miller was, from 2004 to 2008, Vice President of the Global Ruminant Biness with Intervet/Schering Plough Animal Health, which at that time was the largest animal health ruminant biness in the world. From 1998 to 2004, Mr. Miller was General Manager for Schering Plough's Atralia and New Zealand animal health binesses, which included a diversified portfolio of animal health and nutrition products for beef and dairy cattle, sheep, swine, poultry and companion animals. Mr. Miller held numero roles in sales and marketing management during his 17 years with Schering Plough, and prior to that with American Cyanamid Animal Health and Nutrition. He holds a B.S. degree in Animal Science from the University of Nebraska and an Executive MBA degree from the City University of New York. Mr. Miller is a member of the board of trtees of the University of Nebraska Foundation where he also serves on the Finance Committee and is also a member of the board of directors of the Nebraska Innovation Camp Development Corporation of the University of Nebraska Lincoln.